Guest
Signals accepts guest blog posts on topics relevant to stem cells and regenerative medicine, as well as submissions for its Right Turn Friday feature. The opinions, accuracy, completeness and validity of any statements made in guest posts are the responsibility of the author only and not the editor of Signals or CCRM, publisher of Signals. The copyright of this content belongs to the author and any liability with regards to infringement of intellectual property rights remains with the author. To reach the publisher, email info(at)CCRM.ca
Posts by: Guest
Going in for the kill: NK cells enter the immunotherapy arena
Erika Siren lives in Vancouver, British Columbia where she is currently a Ph.D Candidate in the University of British Columbia’s Department of Chemistry. Under the supervision of Dr. Jayachandran Kizhakkedathu, Erika develops biomaterials that can be used to manipulate the immune system. Away from the bench, Erika has a keen interest in the challenges that […]
The long road to commercialization
Carmen Wong completed her PhD studies on creating viruses for cancer research. Since then, she has been working with inventors from universities, accelerators, and startup companies to commercialize their innovations. Carmen was a commercialization analyst with CCRM from 2016-2018. In her free time, Carmen is developing her design skills and hopes to incorporate them into […]
Single-cell RNA sequencing: An emerging superpower in stem cell research
Lyla El-Fayomi is an MSc student in the Molecular Genetics department at the University of Toronto. Under the supervision of Dr. Derek van der Kooy at the Donnelly Centre for Cellular and Biomolecular Research, she is currently studying neural stem cells using single-cell RNA sequencing. She also studies the neurobiology of opiate addiction using optogenetics. […]
A firm hand for the regenerative medicine industry
An experienced cell and gene therapy development executive with extensive surgical and medical clinical experience, Dr. Sven Kili is focused on delivering positive ethical outcomes for patients and customers. Sven is currently the VP and Head of Cell & Gene Therapy Development for GSK Rare Diseases where he led the teams developing a suite of […]